Indaptus Therapeutics closes $24.0 million private placement

Indaptus Therapeutics, Inc. disclosed in an 8-K filed with the SEC that it completed a private placement on October 16, 2026, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended.¹ The company said it would issue an aggregate of 20,338,974 Shares to the Purchasers¹ in connection with the closing.

The transaction traces back to a Stock Purchase Agreement dated September 8, 2026, under which the Company agreed to issue and sell an aggregate of 20,338,974 shares of the Company's common stock, par value $0.01 per share, in a private placement, for aggregate gross proceeds of approximately $24.0 million, before deducting offering expenses.¹

The closing timeline shifted once before the deal was finalized. As disclosed in an earlier Current Report, the Company and the Purchasers entered into notices and consents pursuant to which, among other things, the outside date applicable to each Purchaser under the Purchase Agreement was extended from September 29, 2026 to October 16, 2026.¹

The 8-K was signed on October 20, 2026 by Junyi Dai, the company's Chief Executive Officer.